share_log

Mangoceuticals | CORRESP: CORRESP

Mangoceuticals | CORRESP: CORRESP

Mangoceuticals | CORRESP:信函
美股SEC公告 ·  05/07 13:03

Moomoo AI 已提取核心訊息

Mangoceuticals, Inc. has formally requested the U.S. Securities and Exchange Commission (SEC) to accelerate the effectiveness of its Registration Statement on Form S-1. The initial filing was made on April 23, 2024, and has since been amended. The company, headquartered in Dallas, Texas, seeks to have the registration become effective at 4:30 p.m. EDT on May 9, 2024. This request was communicated through a letter addressed to the SEC, specifically to Juan Grana of the Division of Corporation Finance, and signed by Jacob D. Cohen, Chairman and CEO of Mangoceuticals.
Mangoceuticals, Inc. has formally requested the U.S. Securities and Exchange Commission (SEC) to accelerate the effectiveness of its Registration Statement on Form S-1. The initial filing was made on April 23, 2024, and has since been amended. The company, headquartered in Dallas, Texas, seeks to have the registration become effective at 4:30 p.m. EDT on May 9, 2024. This request was communicated through a letter addressed to the SEC, specifically to Juan Grana of the Division of Corporation Finance, and signed by Jacob D. Cohen, Chairman and CEO of Mangoceuticals.
Mangoceuticals公司已正式向美國證券交易所(SEC)提出請求,加速Form S-1註冊申請書的生效。初次文件提交於2024年4月23日,並已進行修改。總部位於德克薩斯州達拉斯的公司旨在使註冊於2024年5月9日美東時間下午4:30生效。該請求是通過一封致Juan Grana的信件向SEC傳達的,該信件指定爲公司法律事務部主管,由Mangoceuticals的董事長兼首席執行官Jacob D. Cohen簽署。
Mangoceuticals公司已正式向美國證券交易所(SEC)提出請求,加速Form S-1註冊申請書的生效。初次文件提交於2024年4月23日,並已進行修改。總部位於德克薩斯州達拉斯的公司旨在使註冊於2024年5月9日美東時間下午4:30生效。該請求是通過一封致Juan Grana的信件向SEC傳達的,該信件指定爲公司法律事務部主管,由Mangoceuticals的董事長兼首席執行官Jacob D. Cohen簽署。
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息